Jubilant Ingrevia Ltd

AI
Jubilant Ingrev. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Jubilant Ingrevia Ltd

₹ 632 4.35%
27 Oct - close price
jubilantingrevia.com BSE: 543271 NSE: JUBLINGREA
About

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Key Points

Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider.

Website BSE NSE
  • Market Cap ₹ 10,075 Cr.
  • Current Price ₹ 632
  • High / Low ₹ 795 / 535
  • Stock P/E 28.0
  • Book Value ₹ 208
  • Dividend Yield 0.79 %
  • ROCE 11.4 %
  • ROE 9.52 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 34.4%
  • Company's working capital requirements have reduced from 29.4 days to 22.0 days

Cons

  • Stock is trading at 3.04 times its book value
  • Company has a low return on equity of 8.49% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -6.25%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE 500 Nifty 500 BSE Commodities BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
1,020 966 1,074 1,024 1,045 1,057 1,051 1,038 1,121 1,051 1,179 1,300 1,394
902 871 983 915 921 918 905 896 985 924 1,016 1,101 1,182
Operating Profit 118 96 91 110 124 138 147 142 135 126 163 199 212
OPM % 12% 10% 8% 11% 12% 13% 14% 14% 12% 12% 14% 15% 15%
9 9 10 10 10 9 8 11 11 -4 9 10 9
Interest 13 15 14 14 15 12 14 13 12 12 12 17 22
Depreciation 34 34 36 39 40 40 39 41 41 45 48 51 51
Profit before tax 80 55 51 66 80 96 102 100 93 65 112 141 148
Tax % 28% 30% 43% 26% 26% 27% 27% 25% 25% 28% 23% 25% 25%
57 39 29 49 59 69 74 75 69 47 86 106 111
EPS in Rs 3.61 2.42 1.84 3.06 3.70 4.36 4.65 4.71 4.36 2.94 5.43 6.64 7.00
Raw PDF
Upcoming result date: today

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
0 684 4,949 4,773 4,136 4,178 4,388 4,924
0 567 4,108 4,224 3,708 3,658 3,820 4,224
Operating Profit -0 117 841 549 427 519 568 700
OPM % 17% 17% 11% 10% 12% 13% 14%
0 -10 22 32 29 38 27 25
Interest 0 7 31 22 53 56 49 64
Depreciation 0 22 123 122 136 158 175 195
Profit before tax -0 77 709 437 268 344 370 466
Tax % 0% 30% 33% 30% 32% 27% 25%
-0 54 477 308 183 251 278 351
EPS in Rs -3.40 3.41 29.93 19.31 11.48 15.77 17.45 22.01
Dividend Payout % 0% 10% 17% 26% 43% 31% 28%
Compounded Sales Growth
10 Years: %
5 Years: 45%
3 Years: -3%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: 35%
3 Years: -2%
TTM: 25%
Stock Price CAGR
10 Years: %
5 Years: -1%
3 Years: 13%
1 Year: -7%
Return on Equity
10 Years: %
5 Years: 11%
3 Years: 8%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 0.05 16 16 16 16 16 16 16
Reserves -0 1,907 2,417 2,650 2,722 2,911 3,110 3,301
0 556 238 407 740 764 792 895
0 888 1,111 1,176 1,241 1,324 1,551 1,787
Total Liabilities 0 3,366 3,782 4,249 4,719 5,015 5,470 5,999
0 1,805 1,798 1,846 2,539 2,581 3,183 3,157
CWIP 0 65 174 525 331 525 154 281
Investments 0 50 6 8 15 37 33 37
0 1,446 1,804 1,870 1,834 1,872 2,099 2,524
Total Assets 0 3,366 3,782 4,249 4,719 5,015 5,470 5,999

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 112 453 462 430 508 524
0 33 -71 -469 -568 -389 -250
0 -72 -418 42 144 -129 -155
Net Cash Flow 0 73 -36 35 6 -9 119
Free Cash Flow 0 85 225 -16 -136 156 235
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 0% 106% 69% 98% 111% 113% 111%

Ratios

Consolidated / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 251 43 39 50 53 65
Inventory Days 601 117 146 160 163 140
Days Payable 685 103 113 131 141 150
Cash Conversion Cycle 167 57 72 80 75 55
Working Capital Days 220 49 42 37 29 22
ROCE % 8% 29% 16% 10% 11% 11%

Insights

In beta
Mar 2021 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Revenue Share
%

Log in to view insights

Please log in to see hidden values.

Login
Acetic Anhydride Domestic Market Share
%
Number of Products Commercialized
count
Pharma Application Revenue Share
%
R&D Products in Pipeline
count
Specialty Chemicals + Nutrition EBITDA Share
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 45.22% 45.22% 45.22% 45.22% 45.22% 45.22%
6.35% 6.58% 6.55% 7.22% 6.89% 7.12% 6.96% 5.96% 6.15% 6.49% 6.49% 6.93%
11.17% 13.60% 14.07% 15.47% 15.99% 15.91% 21.81% 23.04% 24.00% 24.76% 24.98% 25.18%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.02% 0.02% 0.02% 0.02%
30.17% 27.53% 27.10% 25.09% 24.90% 24.76% 25.30% 24.94% 23.80% 22.53% 22.30% 21.69%
0.82% 0.81% 0.81% 0.77% 0.74% 0.73% 0.72% 0.82% 0.80% 0.98% 0.98% 0.96%
No. of Shareholders 1,62,2021,50,3881,42,7361,25,3671,24,8301,20,4061,23,7481,25,7491,17,5291,12,6961,10,9491,09,650

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls